---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059109"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:13:07.169207+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics Q1 net loss $8.2M; highlights positive CAN-2409 pancreatic cancer survival data

## Summary
- Net loss $8.2M vs $8.8M YoY; R&D expenses $4.1M, G&A $3.8M.
- Cash $25.7M as of March 31, 2024; expected to fund operations into Q4 2024.
- CAN-2409 pancreas phase 2: median OS 28.8 months vs 12.5 months control; 24-month survival 71.4% vs 16.7%.
- Phase 2 CAN-2409 NSCLC topline OS data to be presented at ASCO on June 3, 2024.
- Phase 3 CAN-2409 prostate cancer disease-free survival data expected in Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-059109
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024059109/0000950170-24-059109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024059109/cadl-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059109
- JSON: https://secwatch.observer/filing/0000950170-24-059109.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059109.txt

## Key facts
- Earnings Releases
  Candel Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017024059109/0000950170-24-059109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.